IndustryCompany release
XORTX Therapeutics warns of going-concern doubt as cash falls to $318,846
XORTX Therapeutics Inc. (XRTX) · Mon 16 Nov 2026
The gout and kidney disease developer reports a nine-month net loss of about $2.88M, after a share consolidation and a voluntary TSX Venture delisting.
XORTX Therapeutics, a late-stage company developing therapies for gout and kidney disease, has filed unaudited interim financial statements for the nine months ended 30 September 2026. The statements show a net loss of about $2.88M and cash of $318,846.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): XORTX Therapeutics Inc. ↗
Article written by VigiEye from the official source (XORTX Therapeutics Inc.). Claims are the company's own. AI-assisted; check the source before acting.
More Industry
All →
Merck KGaA to acquire Rapid Micro Biosystems; Q3 revenue rises to $9.5M
🇺🇸 Rapid Micro Biosystems, Inc. (RPID) · Mon 16 Nov 2026
Microbot Medical Q3 revenue falls to $72,000 as gross margin turns negative
🇺🇸 Microbot Medical Inc. (MBOT) · Mon 16 Nov 2026
TOYO Co. reports lower Q3 revenue and net income, but higher nine-month sales
TOYO Co., Ltd (TOYO) · Mon 16 Nov 2026
Eocene unit and Barcode Nanotech develop tumour-targeted nanoparticle form of Aramchol for liver and GI cancers
EoCene Ltd. (EOCN) · Mon 16 Nov 2026
Corbus starts registrational TEMPO-1 trial of Nectin-4 ADC sutantatug envedotin in OPSCC
🇺🇸 Corbus Pharmaceuticals Holdings, Inc. (CRBP) · Mon 16 Nov 2026
Adagio Medical's VT ablation PMA remains under FDA review as board explores strategic alternatives
🇺🇸 Adagio Medical Holdings, Inc. (ADGM) · Mon 16 Nov 2026